Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 3
1957 1
1958 2
1959 2
1960 1
1961 6
1962 1
1964 2
1965 2
1967 1
1970 3
1971 3
1972 1
1975 1
1976 1
1978 1
1980 1
1981 1
1983 3
1984 1
1986 1
1988 4
1989 2
1990 4
1991 3
1994 1
1995 1
1997 2
1999 1
2000 3
2001 4
2002 3
2003 10
2004 7
2005 21
2006 10
2007 12
2008 12
2009 10
2010 9
2011 15
2012 18
2013 17
2014 21
2015 15
2016 5
2017 8
2018 17
2019 9
2020 6
2021 5
2022 8
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for hurwitz h
Search for Hurwit H instead (2 results)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Meric-Bernstam F, et al. Among authors: hurwitz h. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. Lancet Oncol. 2019. PMID: 30857956 Free PMC article. Clinical Trial.
Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer.
Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, Schmoll HJ, Di Maio M. Cremolini C, et al. Among authors: hurwitz h. J Clin Oncol. 2020 Aug 20:JCO2001225. doi: 10.1200/JCO.20.01225. Online ahead of print. J Clin Oncol. 2020. PMID: 32816630 Free article.
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Hainsworth JD, et al. Among authors: hurwitz h. J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. J Clin Oncol. 2018. PMID: 29320312 Clinical Trial.
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Mettu NB, et al. Among authors: hurwitz hi. JAMA Netw Open. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040. JAMA Netw Open. 2022. PMID: 35179586 Free PMC article. Clinical Trial.
Everolimus in colorectal cancer.
Altomare I, Hurwitz H. Altomare I, et al. Among authors: hurwitz h. Expert Opin Pharmacother. 2013 Mar;14(4):505-13. doi: 10.1517/14656566.2013.770473. Epub 2013 Feb 13. Expert Opin Pharmacother. 2013. PMID: 23406528 Review.
Anti-VEGF therapies in the clinic.
Meadows KL, Hurwitz HI. Meadows KL, et al. Among authors: hurwitz hi. Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a006577. doi: 10.1101/cshperspect.a006577. Cold Spring Harb Perspect Med. 2012. PMID: 23028128 Free PMC article. Review.
Angiogenesis pathway inhibitors.
Herbst RS, LoRusso P, Isobe T, Hurwitz HI. Herbst RS, et al. Among authors: hurwitz hi. Cancer Chemother Biol Response Modif. 2005;22:225-45. doi: 10.1016/s0921-4410(04)22010-5. Cancer Chemother Biol Response Modif. 2005. PMID: 16110614 Review. No abstract available.
271 results